|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
143,520,000 |
Market
Cap: |
63.51(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.4425 - $0.4425 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile EyePoint Pharmaceuticals is a pharmaceutical company focused on developing and commercializing therapeutics for patients with eye disorders. Co.'s primary product candidate, EYP-19, is a potential sustained delivery intravitreal anti-VEGF treatment targeting wet age-related macular degeneration. YUTIQ 50 (fluocinolone acetonide intravitreal implant) 0.18 mg for intravitreal injection, is for the treatment of non-infectious uveitis affecting the posterior segment of the eye. DEXYCU® (dexamethasone intraocular suspension) 9%, for intraocular administration, is indicated for the treatment of post-operative ocular inflammation.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
1,431,765 |
4,794,057 |
4,794,057 |
4,794,057 |
Total Buy Value |
$20,571,167 |
$89,496,413 |
$89,496,413 |
$89,496,413 |
Total People Bought |
1 |
1 |
1 |
1 |
Total Buy Transactions |
2 |
6 |
6 |
6 |
Total Shares Sold |
0 |
6,161,499 |
6,722,029 |
6,722,029 |
Total Sell Value |
$0 |
$121,266,413 |
$128,353,600 |
$128,353,600 |
Total People Sold |
0 |
6 |
7 |
7 |
Total Sell Transactions |
0 |
24 |
32 |
32 |
End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Essex Woodlands Ix, Llc |
10% Owner |
|
2018-06-25 |
4 |
B |
$1.27 |
$20,507,955 |
D/D |
16,211,822 |
25,470,390 |
2.45 |
- |
|
Barry James J |
Director |
|
2018-05-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,500 |
12,500 |
|
- |
|
Mazzo David J |
Director |
|
2018-04-20 |
4 |
OE |
$1.13 |
$135,600 |
D/D |
120,000 |
120,500 |
|
- |
|
Essex Woodlands Ix, Llc |
10% Owner |
|
2018-03-28 |
4 |
B |
$1.10 |
$366,149 |
I/I |
332,863 |
8,606,324 |
1.5 |
- |
|
Essex Woodlands Ix, Llc |
10% Owner |
|
2018-03-28 |
4 |
B |
$1.10 |
$9,100,807 |
D/D |
8,273,461 |
8,606,324 |
2.45 |
- |
|
Lurker Nancy |
President & CEO |
|
2018-03-19 |
4 |
A |
$0.00 |
$0 |
D/D |
38,333 |
95,033 |
|
- |
|
Ross Leonard S |
See Remarks |
|
2018-03-19 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
10,000 |
|
- |
|
Paggiarino Dario A. |
Chief Medical Officer |
|
2018-03-19 |
4 |
A |
$0.00 |
$0 |
D/D |
8,333 |
8,333 |
|
- |
|
Lurker Nancy |
President and CEO |
|
2017-06-14 |
4 |
B |
$1.76 |
$99,962 |
D/D |
56,700 |
56,700 |
2.81 |
- |
|
Ashton Paul |
President & CEO |
|
2016-03-18 |
4 |
OE |
$1.13 |
$11,300 |
D/D |
10,000 |
450,741 |
|
- |
|
Ross Leonard S |
Vice President, Finance |
|
2016-01-04 |
4 |
AS |
$4.70 |
$23,500 |
D/D |
(5,000) |
0 |
|
- |
|
Ross Leonard S |
Vice President, Finance |
|
2016-01-04 |
4 |
OE |
$1.81 |
$9,050 |
D/D |
5,000 |
5,000 |
|
- |
|
Ashton Paul |
President & CEO |
|
2015-12-22 |
4 |
AS |
$5.39 |
$646,800 |
D/D |
(120,000) |
440,741 |
|
- |
|
Ashton Paul |
President & CEO |
|
2015-12-22 |
4 |
OE |
$1.13 |
$135,600 |
D/D |
120,000 |
560,741 |
|
- |
|
Ross Leonard S |
Vice President, Finance |
|
2015-12-22 |
4 |
AS |
$5.39 |
$182,991 |
D/D |
(33,950) |
0 |
|
- |
|
Ross Leonard S |
Vice President, Finance |
|
2015-12-22 |
4 |
OE |
$1.81 |
$61,450 |
D/D |
33,950 |
33,950 |
|
- |
|
Ross Leonard S |
Vice President, Finance |
|
2015-12-01 |
4 |
AS |
$4.06 |
$4,263 |
D/D |
(1,050) |
0 |
|
- |
|
Ross Leonard S |
Vice President, Finance |
|
2015-12-01 |
4 |
OE |
$1.81 |
$1,901 |
D/D |
1,050 |
1,050 |
|
- |
|
Ross Leonard S |
Vice President, Finance |
|
2015-08-03 |
4 |
AS |
$4.05 |
$20,250 |
D/D |
(5,000) |
0 |
|
- |
|
Ross Leonard S |
Vice President, Finance |
|
2015-08-03 |
4 |
OE |
$1.81 |
$9,050 |
D/D |
5,000 |
5,000 |
|
- |
|
Ashton Paul |
President & CEO |
|
2014-10-01 |
4 |
AS |
$4.27 |
$42,700 |
D/D |
(10,000) |
440,741 |
|
- |
|
Ashton Paul |
President & CEO |
|
2014-10-01 |
4 |
OE |
$1.13 |
$11,300 |
D/D |
10,000 |
450,741 |
|
- |
|
Ashton Paul |
President & CEO |
|
2014-09-02 |
4 |
AS |
$4.78 |
$47,800 |
D/D |
(10,000) |
440,741 |
|
- |
|
Ashton Paul |
President & CEO |
|
2014-09-02 |
4 |
OE |
$1.13 |
$11,300 |
D/D |
10,000 |
450,741 |
|
- |
|
Ashton Paul |
President & CEO |
|
2014-08-01 |
4 |
AS |
$4.37 |
$43,700 |
D/D |
(10,000) |
440,741 |
|
- |
|
252 Records found
|
|
Page 9 of 11 |
|
|